Changed Risks for REATA PHARMACEUTICALS INC (RETA)

Here are risks that changed year over year. risks from the recent filings of REATA PHARMACEUTICALS INC. Our algorithms work hard to highlight risks unique to this company.

Risks Related to the Development and Commercialization of Our Product Candidates

We may face delays in completing our ongoing or planned clinical trials with Bard and Omav due to a number of factors, or these studies may not be completed at all

If we are unable to continue to advance our development efforts and achieve development milestones under our collaboration agreements due to disagreements, or, if our collaborations are reprioritized by us or our collaborators or are renegotiated, our revenue may decrease and our activities may fail to lead to commercial products